Please assess the completion status of the following clinical trial:

Trial Title: Interventional Study of Mucosal and Antimicrobial Responses to Repeated Vaginal Applications of Tenofovir Gel in HIV Uninfected Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Normal menstrual history with regular cycles and with a minimum of 21 days between menses~* Sexually abstinent or in a stable, mutually monogamous relationship with a partner who is HIV uninfected~* Agree to abstain from sexual intercourse and to not use vaginal products within 48 hours of study entry and for the duration of the study~Exclusion Criteria:~* HIV infected~* Sexually transmitted infection within 6 months of study entry~* Use of nontherapeutic intravenous drugs within 12 months of study entry~* Menopausal~* Currently using hormonal contraception or have used hormonal contraception within 2 months of study entry~* Menstruating at screening or enrollment visits~* Positive urine culture~* Positive chlamydia, gonorrhea, or trichomonas result at screening~* Abnormal Pap smear~* Clinically detectable genital abnormality. More information on this criterion can be found in the protocol.~* History of toxic shock syndrome or a history of symptoms suggesting toxic shock syndrome~* History of intermenstrual bleeding within 3 months of study entry~* Previous gynecologic surgery or have received treatment for syphilis, genital herpes, chlamydia, gonorrhea, trichomonas, or genital warts within 6 months of study entry~* Received treatment for Candida, bacterial vaginosis, or urinary tract infection within 1 month of study entry~* Have douched or used vaginal products, including lubricants, feminine hygiene products, vaginal drying agents, and sex toys within 48 hours of study entry~* Acute or chronic hepatitis B virus infection~* Liver or kidney abnormalities~* Oral antibiotics within 7 days of study entry~* Pregnant, less than 6 months postpartum, or breastfeeding

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): Application of 1% tenofovir gel for 14 consecutive days between menses
- 2 (Type: PLACEBO_COMPARATOR): Application of 1% tenofovir placebo gel for 14 consecutive days between menses

Based on this trial design, predict the completion outcome and termination type (if applicable).